Local serotonin mediates cyclic strain-induced phenotype transformation, matrix degradation, and glycosaminoglycan synthesis in cultured sheep mitral valves

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 10, 2012, Pages

  Lacerda, Carla M R ^a   Kisiday, John ^a   Johnson, Brennan ^a   Christopher Orton, E ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Myxomatous mitral valve disease; Valvular heart disease

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CATHEPSIN K; COLLAGENASE 3; GLYCOSAMINOGLYCAN; INTERSTITIAL COLLAGENASE; MATRIX PROTEIN; MYOSIN; SEROTONIN; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; TRYPTOPHAN HYDROXYLASE;

ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYCLIC STRAIN; GLYCOSAMINOGLYCAN METABOLISM; HEART MUSCLE INJURY; IMMUNOBLOTTING; MITRAL VALVE DISEASE; MUSCLE STRAIN; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SEROTONIN METABOLISM; SHEEP; TENSILE STRENGTH; TISSUE CULTURE;

ACTINS; ANIMALS; BIOMECHANICS; CATHEPSIN K; EXTRACELLULAR MATRIX; GLYCOSAMINOGLYCANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MITRAL VALVE; MYOSINS; ORGAN CULTURE TECHNIQUES; PHENOTYPE; SEROTONIN; SHEEP; TENSILE STRENGTH; TRYPTOPHAN HYDROXYLASE;

EID: 84861147763     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00987.2011     Document Type: Article

References (44)

1. Balachandran K, Bakay MA, Connolly JM, Zhang X, Yoganathan AP, Levy RJ. Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness. Ann Thorac Surg 92: 147-153, 2011.
2. Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am J Physiol Heart Circ Physiol 296: H756-H764, 2009.
3. Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic proteindependent manner. Am J Pathol 177: 49-57, 2010.
4. Barber JE, Kasper FK, Ratliff NB, Cosgrove DM, Griffin BP, Vesely I. Mechanical properties of myxomatous mitral valves. J Thorac Cardiovasc Surg 122: 955-962, 2001.
5. Barber JE, Ratliff NB, Cosgrove DM, Griffin BP III, Vesely I. Myxomatous mitral valve chordae. I: Mechanical properties. J Heart Valve Dis 10: 320-324, 2001.
6. Barzilla JE, Acevedo FE, Grande-Allen KJ. Organ culture as a tool to identify early mechanisms of serotonergic valve disease. J Heart Valve Dis 19: 626-635, 2010.
7. Boudoulas H. Etiology of valvular heart disease. Expert Rev Cardiovasc Ther 1: 523-532, 2003.
8. Combs MD, Yutzey KE. Heart valve development: regulatory networks in development and disease. Circ Res 105: 408-421, 2009.
9. Disatian S, Ehrhart EJ, Zimmerman S III, Orton EC. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation. J Heart Valve Dis 17: 402-411; discussion 412, 2008.
10. Disatian S, Lacerda C, Orton EC. Tryptophan hydroxylase 1 expression is increased in phenotype-altered canine and human degenerative myxomatous mitral valves. J Heart Valve Dis 19: 71-78, 2010.
11. Disatian S, Orton EC. Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease. J Heart Valve Dis 18: 44-51, 2009.
12. Droogmans S, Roosens B, Cosyns B, Degaillier C, Hernot S, Weytjens C, Garbar C, Caveliers V, Pipeleers-Marichal M, Franken PR, Bossuyt A, Schoors D, Lahoutte T, Van Camp G. Dose dependency and reversibility of serotonin-induced valvular heart disease in rats. Cardiovasc Toxicol 9: 134-141, 2009.
13. Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N. 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60: 253-262, 2008.
14. Frank EH, Jin M, Loening AM, Levenston ME, Grodzinsky AJ. A versatile shear and compression apparatus for mechanical stimulation of tissue culture explants. J Biomech 33: 1523-1527, 2000.
15. Grande-Allen KJ, Griffin BP, Ratliff NB, Cosgrove DM, Vesely I. Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations. J Am Coll Cardiol 42: 271-277, 2003.
16. Gu X, Masters KS. Role of the MAPK/ERK pathway in valvular interstitial cell calcification. Am J Physiol Heart Circ Physiol 296: H1748-H1757, 2009.
17. Gupta V, Barzilla JE, Mendez JS, Stephens EH, Lee EL, Collard CD, Laucirica R, Weigel PH, Grande-Allen KJ. Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc Pathol 18: 191-197, 2009.
18. Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin IM. Carcinoid heart disease. Int J Cardiol 129: 318-324, 2008.
19. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 111: 1517-1522, 2005.
20. Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease-it was meant 2B. Pharmacol Ther 132: 146-157, 2011.
21. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol 8: 162-172, 2011.
22. Jerman JC, Brough SJ, Gager T, Wood M, Coldwell MC, Smart D, Middlemiss DN. Pharmacological characterisation of human 5-HT2 receptor subtypes. Eur J Pharmacol 414: 23-30, 2001.
23. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, Levy RJ. Serotonin mechanisms in heart valve disease I: serotonin-induced upregulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 161: 2111-2121, 2002.
24. Krishnamurthy G, Itoh A, Bothe W, Swanson JC, Kuhl E, Karlsson M, Craig Miller D, Ingels NB Jr. Stress-strain behavior of mitral valve leaflets in the beating ovine heart. J Biomech 42: 1909-1916, 2009.
25. Lincoln J, Lange AW, Yutzey KE. Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol 294: 292-302, 2006.
26. Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, Hu Z, Yu W, Jonas B, Pineda R, Calderon-Gay V, Germann M, O'Neill E, Brommage R, Cullinan E, Platt K, Wilson A, Powell D, Sands A, Zambrowicz B, Shi ZC. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 325: 47-55, 2008.
27. MacLean MR, Dempsie Y. Serotonin and pulmonary hypertension-from bench to bedside? Curr Opin Pharmacol 9: 281-286, 2009.
28. Markwald RR, Norris RA, Moreno-Rodriguez R, Levine RA. Developmental basis of adult cardiovascular diseases: valvular heart diseases. Ann NY Acad Sci 1188: 177-183, 2010.
29. Merryman WD, Lukoff HD, Long RA, Engelmayr GC Jr, Hopkins RA, and Sacks MS. Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast. Cardiovasc Pathol 16: 268-276, 2007.
30. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, MacLean MR. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49: 232-236, 2007.
31. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 368: 1005-1011, 2006.
32. Otto CM. Calcific aortic stenosis-time to look more closely at the valve. N Engl J Med 359: 1395-1398, 2008.
33. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 104: 2525-2532, 2001.
34. Roth BL. Drugs and valvular heart disease. N Engl J Med 356: 6-9, 2007.
35. Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 8: 317-329, 2009.
36. Sacks MS, David Merryman W, Schmidt DE. On the biomechanics of heart valve function. J Biomech 42: 1804-1824, 2009.
37. Sacks MS, Enomoto Y, Graybill JR, Merryman WD, Zeeshan A, Yoganathan AP, Levy RJ, Gorman RC, Gorman JH III. In-vivo dynamic deformation of the mitral valve anterior leaflet. Ann Thorac Surg 82: 1369-1377, 2006.
38. Scruggs SM, Disatian S, Orton EC. Serotonin transmembrane transporter is down-regulated in late-stage canine degenerative mitral valve disease. J Vet Cardiol 12: 163-169, 2010.
39. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83: 897-902, 1999.
40. Togashi M, Tamura K, Nitta T, Ishizaki M, Sugisaki Y, Fukuda Y. Role of matrix metalloproteinases and their tissue inhibitor of metalloproteinases in myxomatous change of cardiac floppy valves. Pathol Int 57: 251-259, 2007.
41. Vahanian A, Iung B, Himbert D, Nataf P. Changing demographics of valvular heart disease and impact on surgical and transcatheter valve therapies. Int J Cardiovasc Imaging 27: 1115-1122, 2011.
42. Xu J, Jian B, Chu R, Lu Z, Li Q, Dunlop J, Rosenzweig-Lipson S, McGonigle P, Levy RJ, Liang B. Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 161: 2209-2218, 2002.
43. Yosefy C, Ben Barak A. Floppy mitral valve/mitral valve prolapse and genetics. J Heart Valve Dis 16: 590-595, 2007.
44. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356: 39-46, 2007.